1. Georg-Speyer-Haus, Institute for Tumor Biology and Experimental Therapy, Frankfurt am Main, Germany;
2. Department of Internal Medicine II, Hematology, Oncology, University Hospital Tübingen, Tübingen, Germany;
3. Translational Cancer Epigenomics, Division of Translational Medical Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany;
4. National Center for Tumor Diseases (NCT), Heidelberg, Germany;
5. Division of Cancer Epigenomics, German Cancer Research Center (DKFZ), Heidelberg, Germany;
6. German-Israeli Helmholtz Research School in Cancer Biology, Heidelberg, Germany;
7. Faculty of Biosciences, Ruprecht Karls University of Heidelberg, Heidelberg, Germany;
8. Department of Pathology, St Jude Children's Research Hospital, Memphis, TN;
9. Department of Pediatrics and Adolescent Medicine, University Hospital Erlangen, Erlangen, Germany;
10. Department of Hematology and Oncology, University of Chicago, Chicago, IL;
11. The Ohio State University Comprehensive Cancer Center, Columbus, OH;
12. Institute of Biostatistics and Mathematical Modeling, and
13. Department of Pathology, Goethe University, Frankfurt am Main, Germany;
14. Department of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA;
15. Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, College of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom;
16. Cancer Epigenetics Group, Division of Epigenomics and Cancer Risk Factors, DKFZ, Heidelberg, Germany;
17. Faculty of Medicine, Otto von Guericke University, Magdeburg, Germany;
18. DKFZ, Heidelberg, Germany;
19. German Cancer Consortium (DKTK), Heidelberg, Germany;
20. Frankfurt Cancer Institute, Frankfurt am Main, Germany; and
21. Faculty of Medicine, Goethe University, Frankfurt am Main, Germany